ARTICLE | Clinical News

Hepatitis C vaccine: Phase II start

November 1, 2010 7:00 AM UTC

Next half, Intercell and Romark Laboratories L.C. (Tampa, Fla.) will begin a European Phase II trial in about 60 treatment-naïve patients to compare Intercell's IC41 in combination with Romark's nitazoxanide with or without Pegasys peginterferon alfa-2a vs. Pegasys and Copegus ribavirin.

In March, Intercell and Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) terminated a 2007 deal to co-develop IC41 based on Intercell's expectation to develop IC41 in combination with a small molecule (see BioCentury, March 15). IC41 and nitazoxanide, a nitrothiazolyl-salicylamide compound, are in Phase II and Phase II/III testing, respectively, for HCV. ...